Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been
a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of …

The first dominant SARS‐CoV‐2 Omicron variant BA. 1 harbours 35 mutations in its Spike
protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its …

Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …

After the global spread of the SARS-CoV-2 Omicron BA. 2, some BA. 2 subvariants,
including BA. 2.9. 1, BA. 2.11, BA. 2.12. 1, BA. 4, and BA. 5, emerged in multiple countries …

Abstract The Omicron (B. 1.1. 529) variant of SARS-CoV-2 emerged in November 2021 and
is rapidly spreading among the human population. Although recent reports reveal that the …

Soon after the emergence and global spread of the SARS-CoV-2 Omicron lineage BA. 1,
another Omicron lineage, BA. 2, began outcompeting BA. 1. The results of statistical analysis …

Background Early intramuscular administration of SARS-CoV-2-neutralising monoclonal
antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to …

The severe acute respiratory syndrome coronavirus 2 Omicron BA. 1 sublineage has been
supplanted in many countries by the BA. 2 sublineage. BA. 2 differs from BA. 1 by about 21 …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of
concern evades antibody-mediated immunity that comes from vaccination or infection with …

The severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is spreading rapidly, even in vaccinated individuals, raising concerns about immune …